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Abstract
We studied the interaction between energy metabolism and mitochondrial biogenesis during myogenesis in C2C12
myoblasts. Metabolic rate was nearly constant throughout differentiation, although there was a shift in the relative
importance of glycolytic and oxidative metabolism, accompanied by increases in pyruvate dehydrogenase activation state
and total activity. These changes in mitochondrial bioenergetic parameters observed during differentiation occurred in the
absence of a hypermetabolic stress. A chronic (3 day) energetic stress was imposed on differentiated myotubes using sodium
azide to inhibit oxidative metabolism. When used at low concentrations, azide inhibited more than 70% of cytochrome
oxidase (COX) activity without changes in bioenergetics (either lactate production or creatine phosphorylation) or mRNA
for mitochondrial enzymes. Higher azide concentrations resulted in changes in bioenergetic parameters and increases in
steady state COX II mRNA levels. Azide did not affect mtDNA copy number or mRNA levels for other mitochondrial
transcripts, suggesting azide affects stability, rather than synthesis, of COX II mRNA. These results indicate that changes in
bioenergetics can alter mitochondrial genetic regulation, but that mitochondrial biogenesis accompanying differentiation
occurs in the absence of hypermetabolic challenge. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Genetic control of mitochondrial biogenesis re-
quires the coordinated expression of genes in both
the nucleus and mitochondria. Mitochondrial DNA
(mtDNA) copy number is a primary regulator of
mitochondrial gene expression [1] whereas expression
of nuclear DNA is increased through both transcrip-
tional [2] and post-transcriptional mechanisms [3].
Coordination of nuclear gene transcription is
thought to be achieved by shared activators includ-
ing the nuclear respiratory factor (NRF) family [4],
OXBOX [5], REBOX [6], YY1 [7] and MT1, -3, and
-4 [8,9]. Apart from coordinating nDNA expression,
there is evidence that several of these factors also
in£uence mtDNA replication, transcription and
mRNA processing [9^12]. While an increasing num-
ber of respiratory genes are found to possess these
regulatory elements, the regulatory links between
physiological stressors (i.e. hypermetabolic stress)
and control of respiratory gene expression remain
elusive [13].
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Mitochondrial proliferation occurs in muscle in
response to chronic hypermetabolic conditions,
such as endurance training, electrical stimulation
and hyperthyroidism [13,14]. A number of studies
have demonstrated that factors which decrease met-
abolic rate or mitochondrial e⁄cacy alter the expres-
sion of genes for respiratory proteins, supporting the
hypothesis that prolonged elevations in metabolic
rate directly or indirectly induce mitochondrial en-
zyme synthesis. Tetrodotoxin treatment of neurons
leads to a decrease in mRNA for COX proteins
[15]. Hypoxia exerts a reciprocal control on glyco-
lytic (increase) and mitochondrial (decrease) enzymes
in myotubes [16]. Paralysis of myoblasts, however,
does not lead to changes in the activities of oxidative
enzymes [17]. There is little evidence for direct links
between regulators of metabolic rate (e.g. phospho-
rylation potential [18]) and induction of mitochon-
drial biogenesis under hypermetabolic conditions.
Cytoplasmic translation is regulated by GTP:GDP
ratios [19], although it is not clear if the changes
which occur in vivo are great enough to have phys-
iological relevance [20]. High levels of ATP have
been shown to both inhibit mitochondrial RNA pol-
ymerase activity [21] and stimulate mitochondrial
translation [22].
Di¡erentiation of myoblasts into myocytes is also
accompanied by mitochondrial biogenesis, as indi-
cated by increases in mtDNA, marker enzyme activ-
ities and mRNA levels [16,23^25]. Mitochondria-de-
¢cient myoblasts fail to form into myotubes [26], but
the connections between mitochondrial biogenesis,
myogenesis and bioenergetics have not been estab-
lished. At present, it is not known if the regulatory
control of mitochondrial biogenesis in hypermeta-
bolic adaptation is fundamentally similar to that in
cellular di¡erentiation. In contrast to the apparent
coordinated expression during hypermetabolic chal-
lenges [14], the expression of respiratory genes during
cellular di¡erentiation can be asynchronous [25]. It is
also unknown if the di¡erentiation-induced mito-
chondrial biogenesis is accompanied by changes in
either metabolic rate or bioenergetic regulation.
Although cultured myoblasts are widely used in
studies of mitochondrial biogenesis and myogenesis,
relatively little is known about their metabolic prop-
erties. In the present study, we use an immortalized
mouse skeletal muscle cell line (C2C12) to investigate
the relationship between energy metabolism and mi-
tochondrial biogenesis. We initially consider how
bioenergetics change in response to di¡erentiation.
We then examine the in£uence of azide on respira-
tory gene transcript levels in di¡erentiated myocytes,
since the responsiveness of myocytes to energetic
stress is superimposed upon the intrinsic relation-
ships between respiratory genes and myogenesis.
2. Materials and methods
2.1. Cell culture
C2C12 cells were grown in Dulbecco’s minimum
essential medium (DMEM), containing high glucose,
glutamine and pyruvate, supplemented with 20% fe-
tal bovine serum. At 70% con£uency, the medium
was changed to DMEM supplemented with 2% horse
serum. Penicillin, streptomycin and neomycin were
included in all media. All media, sera and antibiotics
were supplied by Gibco-BRL.
2.2. Enzyme assays
Cultured cells were extracted in 1 ml of enzyme
solubilization medium (20 mM HEPES, pH 7.2,
0.1% Triton X-100, 1 mM EDTA). Citrate synthase
(CS), cytochrome oxidase (COX) and complex I ac-
tivities were assayed spectrophotometrically from
whole cell extracts using previously described proto-
cols [25]. Dichlorophenol-indophenol was used as the
acceptor for complex I assays.
A radiometric assay for pyruvate dehydrogenase
(PDH) was employed to assay both total PDH and
the proportion present in the active, dephospho
form. Cells were extracted in a medium that prevents
changes in phosphorylation (2 mM EDTA, 5 mM
dichloroacetate, 2 mM dithiothreitol, 0.2% Triton
X-100 in 50 mM HEPES, pH 7.7). Conversion of
PDH into its dephospho form was accomplished by
incubation of the cells with uncoupler (10 WM
FCCP) for 10 min prior to extraction. This concen-
tration (in the presence of DMEM+2% horse serum)
gave maximal rates of oxygen consumption in trypsi-
nized suspensions of myoblasts (data not shown).
Higher FCCP concentrations or longer incubations
did not increase measurable PDH activity. Incuba-
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tions were conducted in £asks sealed with rubber
caps which contained a center well holding a glass
¢ber circle (934 AH). Enzyme was added to the assay
medium (2 mM NAD, 0.6 mM coenzyme A, 0.5
mM cocarboxylase, 1 mM dithiothreitol, 1 mM
MgCl2, 0.1% Triton X-100, 20 mM Tris-HCl pH
8.0) for a 4 min pre-incubation in a 37‡C water
bath. The assay was started by addition of pyruvate
(100 WM ¢nal concentration) with approximately
200 000 DPM [14C]1-pyruvate. Incubations were
stopped with 0.1 volume of 70% perchloric acid. Hy-
amine hydroxide (150 Wl) was injected into the center
well and 14CO2 collected for 90 min. Filters were
removed and counted in scintillant containing 0.1%
acetic acid to reduce chemiluminescence. These reac-
tion conditions gave a linear rate of 14CO2 produc-
tion for 20 min, although assays were routinely car-
ried out for only 10 min.
2.3. Metabolic rate determinations
Oxygen consumption was measured in C2C12 cells
at 0, 1, 3, 6, 9 and 12 days of serum starvation.
Culture £asks were ¢lled with a solution of
DMEM/2% horse serum bu¡ered with 6 mM
HEPES and equilibrated to 10% CO2, and oxygen
consumption was monitored polarographically at
37‡C using a Clark-type electrode interfaced with
Vernier Instruments Data Logger software. The
rate of oxidative ATP production per mg protein
was calculated by multiplying the rate of oxygen
consumption by a conversion factor that accounted
for the volume of solution in the £ask, the maximal
saturation of oxygen in water at 37‡C, and the pro-
duction of 5 mol of ATP per mol of consumed O2.
The rate of glycolytic ATP production was also
calculated at 0, 1, 3, 6, 9 and 12 days of serum
starvation by measuring lactate concentrations in
the supernatant. Culture media was replaced with
10 ml fresh DMEM/2% HS on each sampling day,
and an aliquot of the supernatant removed immedi-
ately. Plates were incubated for 4 h, and a second
aliquot of the supernatant was taken. Plates were
washed twice with phosphate bu¡ered saline, and
cells extracted in 1 ml of solubilization medium (20
mM HEPES, pH 7.2, 0.1% Triton X-100, 1 mM
EDTA).
2.4. Metabolite assays
Lactate, phosphocreatine (PCr) and creatine (Cr)
were analyzed using conventional spectrophotomet-
ric techniques modi¢ed for use on microtiter plates.
Lactate was assayed using lactate dehydrogenase
(LDH) and the ‘hydrazine sink’ method. Lactate ox-
idation by LDH leads to equimolar NADH produc-
tion, detectable at 340 nm. Inclusion of hydrazine
and use of high pH ensures the reaction goes to
completion. PCr was assayed using the enzymes cre-
atine phosphokinase (CPK), hexokinase and glucose-
6-phosphate dehydrogenase. Cr was assayed using
the enzymes CPK, pyruvate kinase and LDH. The
ratio of PCr/(PCr+Cr) is an index of energy status,
through interactions of the adenylate pool with crea-
tine pool mediated by endogenous CPK, which is
assumed to be near-equilibrium (by day 6, the onset
of azide treatments, CPK activity has risen to near
maximum activities [25]).
2.5. Mitochondrial mRNA and mtDNA
Total RNA was puri¢ed from guanidinium thio-
cyanate extracts using the acid phenol method. RNA
was glyoxylated and electrophoresed on 1.2% agar-
Table 1
Primer sequence designed for amplifying rat mitochondrial and nuclear DNA gene products
Gene Forward primer (5P-3P) Reverse primer (5P-3P) Annealing T (‡C) Size (bp)
COX I actattcggagcctgagcgg gtgatatggtggaggcagc 58.0 1451
COX III gtccatgaccattaactggagc tgctgcggcttcaaatcc 56.0 678
ADNT1 ggcatcattgattgtgtcgt cctgcacagagacactgaaa 57.5 390
PK gggactgccttcattcagacc cggcatccttacacagcacagg 60.0 1406
COX IV agcctaattggcaag(a/c)gagc gtcgtagtcccacttggc 58.0 468
COX I, III, IV: subunits 1, 3 and 4 of cytochrome c oxidase; PK, pyruvate kinase; ADNT1, adenine nucleotide translocase isoform.
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ose gels. Probes for mtDNA-encoded COX II and
ATPase VI were obtained as previously described
[25]. Probes for COX I, COX III, COX IV, PK
and ADNT1 were constructed as outlined in Table
1. COX III, COX IV, PK and ADNT1 were ampli-
¢ed from ¢rst strand cDNA prepared from total
RNA of rat gastrocnemius, and the nucleotide se-
quence con¢rmed by MOBIX (McMaster University,
Canada). COX I cDNA was ampli¢ed from a plas-
mid containing the entire mouse mitochondrial ge-
nome and a pure PK fragment respectively (both
generously supplied by R.G. Hansford, National In-
stitute of Health). Blots were corrected for loading
di¡erences using a probe for K-tubulin mRNA (gen-
erously supplied by W. Bendena, Queen’s Univer-
sity). The probes for mtDNA and mRNA were ra-
diolabelled using random primers and 32P-dCTP.
Blots were exposed to a phosphoimager screen, and
quanti¢ed using a phosphoimager (Molecular Dy-
namics) driven by Imagequant software.
2.6. Statistical analysis
Signi¢cant di¡erences in steady state mRNA levels
between treatment groups were detected using one-
way ANOVAs, and identi¢ed using Student-New-
man-Keuls test. A repeated measures one-way AN-
OVA was used to test for signi¢cant di¡erences in
the rate of ATP production as a function of time
following serum starvation.
3. Results
3.1. Changes in metabolic rate with di¡erentiation
Metabolic rate was highest in proliferating cells
with approximately 30% of the ATP being contrib-
uted by OXPHOS (Fig. 1b). Once proliferation
ceased, the metabolic rate decreased slightly and
then remained constant throughout the di¡erentia-
tion period. Although the total metabolic rate was
constant, there was a steady shift toward a greater
reliance on mitochondrial pathways (Fig. 1a,b). By
day 12, mitochondrial pathways contributed 61% of
the total ATP used by the cells. This shift was due to
an increase in mitochondrial respiration coupled with
a decrease in glycolytic rate.
Fig. 1. Changes in energy metabolism during di¡erentiating
C2C12 cells. See Section 2 for complete description of tech-
niques. (a) Glycolytic rate. (b) Respiration. (c) Changes in pyru-
vate dehydrogenase activity, expressed as total activity (PDHt,
b) and that present in the active, dephospho form (PDHa, F).
(d) PDHa activity expressed as % of total activity. All data are
presented as mean ( þ S.E.M.).
Fig. 2. E¡ects of acute and chronic azide treatments on C2C12
myoblasts and myotubes. (a) Respiration was measured on cells
collected 1 day after serum starvation. Rates are expressed rela-
tive to the untreated suspension. (b) Chronic e¡ects of low
azide concentrations. Myotubes (day 6) were treated with azide
(10 WM) and sampled over 6 subsequent days for cytochrome
oxidase (b), citrate synthase (F) and complex I (R) activities.
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3.2. Changes in pyruvate dehydrogenase
PDHt increased approximately six-fold (Fig. 2c)
during di¡erentiation. As well as an increase in total
enzyme, there was an increase in the proportion
present in its active, dephospho form (PDHa). In
myoblasts the ratio of PDHa/t was approximately
50%, but as myotubes formed, PDH became increas-
ingly active to the point of being almost completely
activated.
3.3. Azide e¡ects on mitochondrial parameters and
bioenergetics
Acute azide treatment inhibited respiration by
myoblast suspensions with an I50 of approximately
1 mM (Fig. 2a). Chronic low level azide treatment
led to pronounced changes in the activity of COX.
The degree of inhibition increased with time until
reaching a maximum e¡ect by 3 days (Fig. 2b).
The activities of CS and complex I were not a¡ected
by azide.
As much as 70% of COX activity could be inhib-
ited without a¡ecting lactate production (Fig. 3a),
creatine phosphorylation (Fig. 3b) or steady state
levels of COX II mRNA (Fig. 4a). Greater degrees
of inhibition stimulated glycolysis (Fig. 3a), de-
creased creatine phosphorylation (Fig. 3b) and in-
creased COX II mRNA approximately four-fold
(n = 3) (Fig. 4b, Fig. 5). While mitochondrial DNA
copy number was una¡ected by the degree of COX
inhibition (Fig. 4a), COX II mRNA levels were high-
est following 3 days of azide treatment (Fig. 6a).
Steady state levels of other mitochondrial and nu-
clear mRNAs were unchanged using identical azide
treatment protocols (Fig. 6b).Fig. 3. E¡ects of azide concentration on C2C12 enzymes and
bioenergetic parameters. Myotubes (day 6) were treated with
various azide concentrations (0^500 WM) for 3 days. (a) Lactate
production over 24 h was measured in the culture medium.
Plates were washed and extracted for cytochrome oxidase activ-
ity and protein determinations. Data are expressed relative to
the activity in untreated control. Paired data were ranked by
degree of inhibition of COX. Each data point represents 10 sep-
arate determinations. (b) Creatine (Cr) and phosphocreatine
(PCr) were measured after 3 days azide treatment. The degree
of COX inhibition was determined on parallel plates. Cells were
given fresh medium 4 h before sampling. Plates were quickly
rinsed in ice-cold phosphate bu¡ered saline then extracted im-
mediately in 7% perchloric acid.
Fig. 4. Changes in mtDNA and mRNA in relation to azide
treatment. Cells were treated with various azide concentrations
for 3 days beginning at 6 days of serum starvation. Two series
of plates were harvested for enzyme analysis, then subsequently
extracted for DNA. A third series was extracted for total
RNA. 32P-dCTP labelled COX II was used as a probe for both
the mtDNA dot blot and the Northern blot (10 Wg RNA/lane).
Data for mtDNA copy number are presented as mean of two
separate azide titrations (each point in triplicate). Degree of
COX inhibition is expressed relative to untreated control.
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4. Discussion
4.1. Mitochondrial energetics in proliferating cells
Undi¡erentiated C2C12 myoblasts appear similar
to tumor cells in their dependence upon glycolysis
[27]. Despite the availability of oxidizable fuels (glu-
cose, pyruvate, amino acids) much of the energy re-
quired for proliferation is derived from glycolysis. In
the earliest stages of di¡erentiation, approximately
60% of the energy demands of the cell are met by
lactate production from glucose (Fig. 1a). However,
several lines of evidence suggest this reliance upon
anaerobic glycolysis is not due to mitochondrial in-
adequacy. Addition of an uncoupler of OXPHOS
(FCCP) more than doubles the respiration rate of
suspended myoblasts (data not shown), suggesting
mitochondria are capable of greater £ux under the
appropriate regulatory in£uences. The activity of
PDHa (3.6 nmol/min/mg protein, Fig. 1c), the ¢rst
step in oxidation of mitochondrial pyruvate, suggests
a capacity to yield 54 nmol ATP/min/mg protein
(3.6U15 ATP/pyruvate oxidized), compared to an
observed rate of oxidative ATP production of 25
nmol/min/mg protein (Fig. 1b). Furthermore, only
50% of PDH in myoblasts is present in its active,
dephospho form. In many oxidative tissues, changes
in PDHa/t accompany changes in energetic demands
[28]. These observations suggest that oxidative me-
tabolism could meet the bioenergetic demands of
proliferating cells under the appropriate regulatory
conditions.
4.2. Mitochondrial energetics during myogenesis
In mammalian skeletal muscle, hypermetabolic
Fig. 5. Representative autoradiographs of mRNA levels in
C2C12 cells treated 3 days with azide. Each panel is a autora-
diograph of blot of a 1.2% agarose gel using 5 Wg (B and D)
or 20 Wg (A and C) glyoxylated total RNA per lane. (A) ATP-
ase VI; (B) ADNT1; (C) K-tubulin; (D) COX II. In each pan-
el, the left lane is 0 azide, center 50 WM, right 500 WM. Azide
treatment increased lactate production two-fold at 50 WM and
¢ve-fold at 500 WM.
Fig. 6. Levels of mRNA in C2C12 cells treated with azide. All
data were obtained by probing total RNA blots (5 Wg for mito-
chondrial signals, 25 Wg for nuclear signals) with 32P-dCTP la-
belled cDNA probes, normalized with K-tubulin, and expressed
relative to control. (a) Changes in COX II mRNA levels in
control (b) and azide-treated (F) (500 WM) C2C12 cells over 6
days relative to day 0 control. (b) mRNA levels relative to con-
trol for mitochondrial and nuclear transcripts in C2C12 cells
treated with 50 WM (open bar) and 500 WM (closed bar) azide
for 3 days (* denotes signi¢cant di¡erence; P6 0.05).
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treatments such as exercise training and chronic elec-
trical stimulation lead to mitochondrial proliferation
[13,14]. It is not clear if mitochondrial biogenesis is
induced directly by neural/hormonal factors or indi-
rectly from persistent disturbances in energy metab-
olism arising through the recruitment pattern. In mi-
tochondrial myopathies, the resulting bioenergetic
disturbance may induce expression of the nuclear-
encoded respiratory genes ADNT1 and ATPL [29].
It is unlikely that, during myogenesis, metabolic de-
mand per se is the ultimate cause of mitochondrial
biogenesis, given that the metabolic rate during dif-
ferentiation (Fig. 1a,b, sum of oxidative and glyco-
lytic rates) is relatively constant at 55^85 nmol ATP/
min/mg protein.
Manifold changes in the activity of PDH (Fig.
1c,d) and other mitochondrial enzymes [25] coincided
with a shift in energy metabolism from primarily
glycolytic (66%) to predominantly oxidative (60%).
A fundamental change in the relationship between
glycolysis and respiration is also predicted in pre-
vious studies which showed a shift in adenine nucleo-
tide translocase (ADNT) isoform expression.
ADNT2 is an isoform expressed in glycolytic tissues
whereas ADNT1 predominates in oxidative tissues
such as skeletal and cardiac muscles. In C2C12 my-
oblasts, levels of mRNA decline for ADNT2 but in-
crease for ADNT1 with the onset of di¡erentiation
and myotube formation [30]. Although there is no
direct evidence for functional di¡erences in the iso-
forms, the tissue distribution suggests ADNT2 may
have a role in transferring glycolytic ATP into mito-
chondria (see [30]).
The elevated oxidative capacity accompanying
C2C12 di¡erentiation is perhaps best illustrated by
the changes in the capacity for £ux through PDH
(Fig. 1c). The calculated maximal £ux through myo-
blast PDHa is 54 nmol ATP/min/mg (PDHa = 3.6
nmol/min/mgU15 nmol ATP/nmol pyruvate). This
capacity approaches that predicted from respiration
studies (25 nmol/min/mg) (Fig. 1b). During myogen-
esis there was a pronounced increase in both PDHt
(Fig. 1c) and PDH activation state (Fig. 1d), leading
to an increase in capacity to 480 nmol ATP/min/mg
(15 nmol ATP/nmol pyruvateU32 nmol/min/mg
PDHa, Fig. 1c), 12.5-fold greater than that which
would account for oxidative ATP requirements
(37.5 nmol/min/mg, Fig. 1b). The increased capacity
and high PDH activation state do not re£ect a cel-
lular response to an increased metabolic demand, as
metabolic rate did not increase during di¡erentiation
(Fig. 1a). It can further be argued that the di¡eren-
tiating cell was not in an energetic de¢cit as glyco-
lytic £ux actually declined during myogenesis (Fig.
1a). This disparity suggests that regulatory condi-
tions within the mitochondria (acetyl CoA/CoA,
NADH/NAD, Ca2) were highly favorable for
PDH interconversion towards PDHa, but were not
necessarily indicative of energetic demand. There is
some potential for these same regulatory factors to
in£uence myogenesis and mitochondrial biogenesis.
REBOX factor binds to the element in an NADH-
dependent manner [6], although the conditions re-
quired (0^15 mM NADH) are not physiologically
realistic. Ca2 is an important regulator of both
myogenesis and bioenergetics. Myogenesis is strictly
dependent on the extracellular Ca2 concentration
[31]. The Ca2 ionophore A23187 leads to an in-
crease in expression of mitochondrial enzymes in pri-
mary cultures of rat muscle cells [17]. Thus, it has not
been established if any of these bioenergetic regula-
tors directly or indirectly in£uence mitochondrial
gene expression. More information exists, at present,
on the presence of cis-elements of nuclear-encoded
mitochondrial genes than control of expression of
trans-factors binding to these elements.
4.3. Azide e¡ects on mitochondrial energetics and
gene expression
Azide is a well known non-competitive inhibitor of
COX, in this study demonstrating an I50 of approx-
imately 1 mM (Fig. 2a). However, chronic treatment
of C2C12 cells with azide in the WM range also re-
versibly decreases COX activity (Fig. 2b). Bennett et
al. [32] treated rats with low levels of azide via os-
motic pumps and created Alzheimer-like symptoms,
including a depression of measurable COX activity.
Chandel et al. [33] found that chronic hypoxia re-
duced the COX catalytic activity, although the mech-
anism by which this occurs is unclear. Similarly, the
molecular mechanism by which low levels of azide
inhibits COX activity is unknown. It did allow us
to introduce small, measurable degrees of metabolic
inhibition to examine the relationship between meta-
bolic stress, mitochondrial energetics and gene ex-
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pression. The azide e¡ects were speci¢c to COX, as
neither CS nor complex I activity was a¡ected (Fig.
2b). Azide did not cause changes in lactate produc-
tion (Fig. 3a) or creatine phosphorylation (Fig. 3b)
until more than 70% of the COX activity was inhib-
ited.
E¡ects on COX II mRNA levels coincided with
the point in the azide titration where e¡ects on bio-
energetic parameters were apparent (70% inhibition
of COX). However, the changes in COX II mRNA
with azide treatment are likely due to post-transcrip-
tional regulation (e.g. mRNA stability) rather than
an increased rate of transcription. Mitochondrial
transcription is generally thought to be regulated
by gene ampli¢cation and azide did not a¡ect
mtDNA copy number (Fig. 4a). Also, because of
the polycistronic transcript, mRNA for COX II is
synthesized stoichiometrically with COX I, COX
III, and ATPase VI mRNA, the levels of which did
not change with azide treatment (Fig. 5).
Although these results argue for an azide-induced
increase in COX II mRNA stability, the mechanism
by which this occurs is not clear. There is evidence
for the presence of cytoplasmic proteins which bind
the 3P untranslated region of mRNA of liver iso-
forms of COX VIIa, VIII [34] and VIa [35]. How-
ever, there is no evidence for COX mRNA binding
proteins within mitochondria. Changes in mitochon-
drial mRNA stability have been reported in develop-
ing rat liver [36] but the e¡ect is not selective as all
mRNA species are more stable. If the increase in
COX II mRNA is due to stability, the nature of
the azide sensitivity of the process is unknown. Yeast
possess an NTP dependent exonuclease which con-
trols mtRNA turnover [37]. A number of pathways
have been shown to be sensitive to either hypoxia or
azide. Hypoxia exerts a reciprocal control on tran-
scription of glycolytic (increase) and mitochondrial
(decrease) enzymes [16]. It has since been shown
that the e¡ects on glycolytic enzymes may be medi-
ated by the oxygen sensitive transcription factor HIF
(hypoxia-inducible factor). Some genes have been
shown to be similarly sensitive to both hypoxia and
azide, suggesting an oxygen independent regulatory
pathway (see [38]). To our knowledge there is no
evidence for a similar pathway regulating activity
of mRNA binding proteins, particularly for mRNA
species located within mitochondria.
In summary, pronounced changes in mitochondria
and bioenergetics occurred during myogenesis in the
absence of a hypermetabolic challenge. When meta-
bolic conditions were perturbed directly by azide, at
least one species of mitochondrial mRNA increases,
likely due to an increase in mRNA stability.
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